| Irmalynn Mooneyham, NP | |
|
266 Joule St, Alcoa, TN 37701-2422 | |
| (865) 984-3864 | |
| (865) 380-4095 |
| Full Name | Irmalynn Mooneyham |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 11 Years |
| Location | 266 Joule St, Alcoa, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225470057 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 17789 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Crossroads Urgent Care Pllc | 8325117484 | 139 |
| Dx Mso Pllc | 7719131101 | 74 |
News Archive
Clinical trials in which participants are randomly assigned to different treatments by design are the cornerstone of clinical research. When conducted correctly, it's widely accepted by the research community that the results are valid and can be trusted.
Researchers from the University of Bristol found that an entire population that wears masks in public leads to a reduction in the transmission of SARS-CoV-2 by almost 26%.
The U.S. Food and Drug Administration today allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning.
Building on a tool that they developed in yeast four years ago, researchers at the Johns Hopkins University School of Medicine scanned the human genome and discovered what they believe is the reason people have such a variety of physical traits and disease risks.
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.
› Verified 5 days ago
| Entity Name | Blount Memorial Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699710194 PECOS PAC ID: 6406844174 Enrollment ID: O20040503000547 |
News Archive
Clinical trials in which participants are randomly assigned to different treatments by design are the cornerstone of clinical research. When conducted correctly, it's widely accepted by the research community that the results are valid and can be trusted.
Researchers from the University of Bristol found that an entire population that wears masks in public leads to a reduction in the transmission of SARS-CoV-2 by almost 26%.
The U.S. Food and Drug Administration today allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning.
Building on a tool that they developed in yeast four years ago, researchers at the Johns Hopkins University School of Medicine scanned the human genome and discovered what they believe is the reason people have such a variety of physical traits and disease risks.
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.
› Verified 5 days ago
| Entity Name | Rutherford County Primary Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114973237 PECOS PAC ID: 6305819483 Enrollment ID: O20040817000631 |
News Archive
Clinical trials in which participants are randomly assigned to different treatments by design are the cornerstone of clinical research. When conducted correctly, it's widely accepted by the research community that the results are valid and can be trusted.
Researchers from the University of Bristol found that an entire population that wears masks in public leads to a reduction in the transmission of SARS-CoV-2 by almost 26%.
The U.S. Food and Drug Administration today allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning.
Building on a tool that they developed in yeast four years ago, researchers at the Johns Hopkins University School of Medicine scanned the human genome and discovered what they believe is the reason people have such a variety of physical traits and disease risks.
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.
› Verified 5 days ago
| Entity Name | Crossroads Urgent Care Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366644361 PECOS PAC ID: 8325117484 Enrollment ID: O20080515000672 |
News Archive
Clinical trials in which participants are randomly assigned to different treatments by design are the cornerstone of clinical research. When conducted correctly, it's widely accepted by the research community that the results are valid and can be trusted.
Researchers from the University of Bristol found that an entire population that wears masks in public leads to a reduction in the transmission of SARS-CoV-2 by almost 26%.
The U.S. Food and Drug Administration today allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning.
Building on a tool that they developed in yeast four years ago, researchers at the Johns Hopkins University School of Medicine scanned the human genome and discovered what they believe is the reason people have such a variety of physical traits and disease risks.
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.
› Verified 5 days ago
| Entity Name | Dx Mso Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225381148 PECOS PAC ID: 7719131101 Enrollment ID: O20130213000017 |
News Archive
Clinical trials in which participants are randomly assigned to different treatments by design are the cornerstone of clinical research. When conducted correctly, it's widely accepted by the research community that the results are valid and can be trusted.
Researchers from the University of Bristol found that an entire population that wears masks in public leads to a reduction in the transmission of SARS-CoV-2 by almost 26%.
The U.S. Food and Drug Administration today allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning.
Building on a tool that they developed in yeast four years ago, researchers at the Johns Hopkins University School of Medicine scanned the human genome and discovered what they believe is the reason people have such a variety of physical traits and disease risks.
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.
› Verified 5 days ago
| Entity Name | App Of Tennessee Hm, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396160768 PECOS PAC ID: 5395960694 Enrollment ID: O20140630001088 |
News Archive
Clinical trials in which participants are randomly assigned to different treatments by design are the cornerstone of clinical research. When conducted correctly, it's widely accepted by the research community that the results are valid and can be trusted.
Researchers from the University of Bristol found that an entire population that wears masks in public leads to a reduction in the transmission of SARS-CoV-2 by almost 26%.
The U.S. Food and Drug Administration today allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning.
Building on a tool that they developed in yeast four years ago, researchers at the Johns Hopkins University School of Medicine scanned the human genome and discovered what they believe is the reason people have such a variety of physical traits and disease risks.
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.
› Verified 5 days ago
| Entity Name | Visavis Health Care Medical Group Of Tn Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407639172 PECOS PAC ID: 1557717683 Enrollment ID: O20231026001239 |
News Archive
Clinical trials in which participants are randomly assigned to different treatments by design are the cornerstone of clinical research. When conducted correctly, it's widely accepted by the research community that the results are valid and can be trusted.
Researchers from the University of Bristol found that an entire population that wears masks in public leads to a reduction in the transmission of SARS-CoV-2 by almost 26%.
The U.S. Food and Drug Administration today allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning.
Building on a tool that they developed in yeast four years ago, researchers at the Johns Hopkins University School of Medicine scanned the human genome and discovered what they believe is the reason people have such a variety of physical traits and disease risks.
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Irmalynn Mooneyham, NP 103 W Broadway Ave, Maryville, TN 37801-4703 Ph: (865) 273-1752 | Irmalynn Mooneyham, NP 266 Joule St, Alcoa, TN 37701-2422 Ph: (865) 984-3864 |
News Archive
Clinical trials in which participants are randomly assigned to different treatments by design are the cornerstone of clinical research. When conducted correctly, it's widely accepted by the research community that the results are valid and can be trusted.
Researchers from the University of Bristol found that an entire population that wears masks in public leads to a reduction in the transmission of SARS-CoV-2 by almost 26%.
The U.S. Food and Drug Administration today allowed marketing of a new device, ClearMate, intended to be used in an emergency room setting to help treat patients suffering from carbon monoxide poisoning.
Building on a tool that they developed in yeast four years ago, researchers at the Johns Hopkins University School of Medicine scanned the human genome and discovered what they believe is the reason people have such a variety of physical traits and disease risks.
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.
› Verified 5 days ago
Melanie Bankerd, F.N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 Fax: 865-380-4095 | |
Katherine Elizabeth Whittington, MSN, PMHNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 255 E Watt St, Alcoa, TN 37701 Phone: 865-273-1616 Fax: 865-273-1645 | |
Michael E Lowe, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 212 Heighton Ct, Alcoa, TN 37701 Phone: 865-556-2672 | |
Caytlin Grae Cardwell, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 255 E Watt St, Alcoa, TN 37701 Phone: 865-273-1616 Fax: 865-273-1645 | |
Mrs. Lori M. Ervin, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 | |
Lauren E Monroe, ANP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 Fax: 865-380-4095 | |
Summer Dobbs Brooks, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 266 Joule St, Alcoa, TN 37701 Phone: 865-984-3864 Fax: 865-380-4095 |